AI-Generated Summary

The Trump administration has announced a 100% tariff on imported patented drugs, effective October 1, unless manufacturers establish U.S.-based production facilities. This significant policy shift targets global pharmaceutical exporters, including major Indian firms, and is expected to profoundly impact international supply chains and investment strategies within the sector.

In a nutshell

This move represents a forceful push towards domestic pharmaceutical manufacturing, potentially leading to substantial restructuring for international pharma companies and raising questions about drug pricing and availability in the U.S. market.

Source: The Economic Times